Results Expected in 2026-2027
Several studies in this registry are expected to report results in the near term. Table Results Expected in 2026-2027 highlights those with the highest potential impact on ME/CFS understanding and treatment.
#landscape[
| Study | Expected | Why it matters |
|---|---|---|
| DecodeME | Mid–late 2026 | First adequately powered GWAS (\(n>20,000\)); could identify causal genetic loci and enable Mendelian randomisation |
| BC007 Phase II | 2026 | Largest RCT (\(n=114\)) testing autoantibody-targeted therapy; validates or refutes the functional GPCR autoantibody hypothesis |
| RECOVER-TLC | End of 2026 | First-round results (baricitinib, structured pacing); largest federally funded treatment trials relevant to ME/CFS |
| BioQuest | 2026–2027 | Largest ME/CFS biomarker study (\(n=1,000\)); could yield first validated blood-based diagnostic panel with disease controls |
| BioMapAI | 2026–2027 | Longitudinal multi-omics follow-up; will distinguish state vs trait markers over 4-year disease trajectory |
| ADDRESS-LC | H1 2026 | First CNS-penetrant NF-\(\kappa\)B modulator for Long Covid brain fog; cross-disease (Alzheimer’s, Parkinson’s) data available |
| Cornell NAC-GSH | ~2026 | First dose-response study of NAC on brain glutathione (MRS); could validate oxidative stress as druggable CNS target |
| NSU Probiotics | ~2026 | First ME/CFS-specific probiotic RCT with IBS stratification; tests gut–brain axis hypothesis directly |
| OMF Kynurenine | ~2026 | First RCT testing kynurenine supplementation; probes tryptophan–serotonin–neuroinflammation axis |
| Berlin Conference | May 2026 | Major venue for unpublished data; BC007, HBOT, and LDN results may be presented |
| Nacul LDN RCT | Early 2026 | First double-blind ME/CFS-specific LDN trial with inflammatory markers and QoL endpoints |
:::
Recently published results to monitor for follow-up studies. Multiple registry entries have reported results that may generate replication or extension studies in 2026–2027:
RESTORE-ME (oxaloacetate): Positive RCT (\(p=0.0039\) for fatigue reduction); independent replication needed.
STOP-PASC / PAX LC (Paxlovid): Negative results challenge the viral persistence hypothesis; redirects research toward post-infectious immune and metabolic mechanisms.
Stellate ganglion block: Promising pilot (\(n=10\)) for autonomic reset; larger sham-controlled RCT likely in planning.
HBOT pilot: Thalamic hyperconnectivity normalised in 30 ME/CFS patients; sham-controlled RCT needed.
Cornell cfRNA: Liquid biopsy classifier (AUC 0.81); multi-site validation with disease controls required.
Palomo herpesvirus reactivation: Multi-virus co-reactivation in 72.5% of patients; anti-dUTPase IgG as potential stratification marker.
JAX microbiome AI: 90% diagnostic accuracy from multimodal gut/blood data; blinded independent replication needed.
Post-IM 7-year cohort: 4% locked-in ME/CFS rate at 24 months; risk factor analysis pending.
IA-PACS-CFS and EXTINCT: Two sham-controlled immunoadsorption RCTs completed (n=66 and n=63); results pending as of April 2026. Will be the first placebo-controlled tests of autoantibody removal in ME/CFS.
Anft et al. 2025: Independent-centre IA study (n=12) showed autoantibody elimination but non-significant symptom improvement (Anft et al. 2025); rebound within 1 month.
IMPACT trial: First study measuring memory B-cell dynamics after IA (n=50, recruiting); may explain relapse mechanism.